| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-10 |
| Cash Flow (TTM) (Millions $) |
-2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Adynxx, Inc. is a biotechnology company based in San Francisco, California that focuses on developing novel therapeutics for the prevention and treatment of pain. The company specializes in the field of neuroinflammation and aims to address the underlying cause of pain rather than just managing the symptoms.
Adynxx utilizes its proprietary Transcription Factor Decoy (TFD) platform technology to target genes involved in the transition from acute to chronic pain. By intercepting and inhibiting these genes, the company aims to prevent pain sensitization and the development of chronic pain conditions.
The company's pipeline includes potential drug candidates for various pain conditions, including post-surgical pain, neuropathic pain, and chronic lower back pain. These candidates aim to provide long-lasting pain relief, reduce the need for opioids, and potentially improve patient outcomes.
Adynxx is committed to advancing pain management by utilizing innovative approaches and cutting-edge research. Its ultimate goal is to develop transformative therapies that can positively impact the lives of patients suffering from chronic pain.
|
0.000%